The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

August 1, 2024

Conditions

Allergic Contact Dermatitis

Interventions

DRUG

Anakinra

100 mg Anakinra injections s.c.

DRUG

Sodium Chloride 9mg/ml Injection

9 mg Sodium Chloride injections s.c.

Trial Locations (1)

Gentofte Hospital, Hellerup

All Listed Sponsors

lead

Herlev and Gentofte Hospital

OTHER